Recent investigations have centered on the intersection of GLP-1|GIP|GCGR stimulant therapies and dopaminergic signaling. While GIP agonists are commonly employed for managing type 2 diabetes mellitus, their potential consequences on reinforcement circuits, specifically influenced by DA systems, are receiving considerable interest. This paper detai